Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutationsIntroductionEpidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) afatinib, erlotinib, and gefitinib are an esta...

Full description

Bibliographic Details
Main Authors: Adolfo Favaretto, Francesco Grossi, Alessandro Morabito, Roberto Ravasio
Format: Article
Language:English
Published: AboutScience Srl 2017-08-01
Series:Global & Regional Health Technology Assessment
Online Access:http://www.grhta.com/Attach/0A3736DD-1579-4AC9-9216-63F6C22391E7/8E8523D7-FDC6-42CB-9136-80182956060F

Internet

http://www.grhta.com/Attach/0A3736DD-1579-4AC9-9216-63F6C22391E7/8E8523D7-FDC6-42CB-9136-80182956060F

Similar Items